Loading...
Market Growth Forecast: The cystic fibrosis (CF) market in the seven major markets (7MM) is projected to grow from $11.1 billion in 2024 to $16.0 billion by 2034, driven primarily by CFTR modulators, which are expected to dominate the treatment landscape.
Vertex Pharmaceuticals' Dominance: Vertex Pharmaceuticals leads the CF market with its CFTR modulator portfolio, including the gold standard Trikafta/Kaftrio and the next-generation Alyftrek, which is anticipated to maintain a significant market share despite emerging competition from new therapeutic modalities and potential generic entries.
